Ishara Investments LP Buys Shares of 88,000 Biohaven Ltd. $BHVN

Ishara Investments LP bought a new stake in shares of Biohaven Ltd. (NYSE:BHVN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 88,000 shares of the company’s stock, valued at approximately $994,000. Ishara Investments LP owned 0.08% of Biohaven as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in BHVN. Infinitum Asset Management LLC increased its position in Biohaven by 267.6% during the 4th quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company’s stock valued at $70,562,000 after purchasing an additional 4,550,000 shares during the period. Stifel Financial Corp increased its position in Biohaven by 50.3% during the 4th quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock valued at $112,221,000 after purchasing an additional 3,328,506 shares during the period. Schonfeld Strategic Advisors LLC increased its position in Biohaven by 3,829.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 1,606,777 shares of the company’s stock valued at $18,141,000 after purchasing an additional 1,565,891 shares during the period. Vanguard Group Inc. increased its position in Biohaven by 52.9% during the 4th quarter. Vanguard Group Inc. now owns 4,395,946 shares of the company’s stock valued at $49,630,000 after purchasing an additional 1,520,756 shares during the period. Finally, State Street Corp increased its position in Biohaven by 34.2% during the 4th quarter. State Street Corp now owns 5,716,487 shares of the company’s stock valued at $64,539,000 after purchasing an additional 1,458,204 shares during the period. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Leerink Partners reissued an “outperform” rating and set a $15.00 target price on shares of Biohaven in a research report on Tuesday, March 3rd. Wall Street Zen downgraded shares of Biohaven from a “sell” rating to a “strong sell” rating in a research report on Sunday, April 26th. Royal Bank Of Canada cut their target price on shares of Biohaven from $23.00 to $22.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. Citigroup raised their target price on shares of Biohaven from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. Finally, Canaccord Genuity Group assumed coverage on shares of Biohaven in a research report on Monday, April 13th. They issued a “buy” rating and a $21.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.27.

Biohaven Stock Up 13.2%

Shares of Biohaven stock opened at $13.69 on Thursday. The company has a market cap of $2.06 billion, a P/E ratio of -2.41 and a beta of 1.35. Biohaven Ltd. has a 52-week low of $7.48 and a 52-week high of $18.57. The company has a quick ratio of 7.41, a current ratio of 7.41 and a debt-to-equity ratio of 1.87. The firm’s 50 day moving average price is $10.18 and its 200-day moving average price is $10.57.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, May 4th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). On average, sell-side analysts predict that Biohaven Ltd. will post -3.07 EPS for the current fiscal year.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.